Announcements
- Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate
- Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study
- Addex Announces Participation in the H.C. Wainwright Global Investment Conference
- Addex Announces Participation in the 22nd Bio€quity Europe Conference
- Addex Shareholders Approve All Resolutions at Annual General Meeting
- Addex Reports Q1 2022 Financial Results
- Addex to Present at the Swiss Biotech Day 2022
- Addex to Present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference
- Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study
- Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders
More ▼
Key statistics
SmartText not available for this item.
52-week range
Markit short selling activity
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 1.37 |
Average volume | -- |
---|---|
Shares outstanding | 65.27m |
Free float | 59.29m |
P/E (TTM) | -- |
Market cap | 12.79m CHF |
EPS (TTM) | -0.5203 CHF |
Data delayed at least 15 minutes, as of Jun 28 2019 14:58 BST.
More ▼